Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizumab, in Subjects with Newly Diagnosed Acute Graft Versus Host Disease

Blood (2019) 134 (Supplement_1): 4516.

https://doi.org/10.1182/blood-2019-127325

Published: 2019

Journal Articles

Pre-Transplant Monocytic Myeloid-Derived Suppressor Cell Frequency Has No Prognostic Role for Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Remission

Colin Godwin, Jonathan R. Fromm, MD PhD, Brenda M. Sandmaier, MD, Marco Mielcarek, MD, Brent Wood, MD PhD, Frederick R. Appelbaum, MD, Rainer F. Storb, MD, Roland B. Walter, MD PhD MS

Blood (2018) 132 (Supplement 1): 5255.

https://doi.org/10.1182/blood-2018-99-117745

Published: 2018

Journal Articles

Sirolimus Combined with Mycophenolate Mofetil (MMF) and Cyclosporine (CSP) Significantly Improves Prevention of Acute Graft-Versus-Host-Disease (GVHD) after Unrelated Hematopoietic Cell Transplantation (HCT): Results from a Phase III Randomized Multi-Center Trial

Brenda M Sandmaier, MD, David G Maloney, MD PhD, Barry E. Storer, PhD, Gitte Olesen, MD, Michael B. Maris, MD, Jonathan A Gutman, MD, Soren Lykke Petersen, MD DMSC, Amelia Langston, MD, Thomas Chauncey, Wolfgang Bethge, MD, Michael A Pulsipher, MD, Brian Thomas Kornblit, MD PhD, Ann E Woolfrey, MD, Marco Mielcarek, MD, Paul J. Martin, MD, Mary E.D. Flowers, MD, Rainer F. Storb, MD

Blood (2016) 128 (22): 506.

https://doi.org/10.1182/blood.V128.22.506.506

Published: 2016

Journal Articles

Significance of Peri-Transplant Dynamics of Minimal Residual Disease (MRD) in Adults with Acute Myeloid Leukemia (AML) in Morphological Remission Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation

Yi Zhou, MD PhD, Daisuke Araki, MD, Megan Othus, PhD, Jerald P. Radich, MD, Anna B. Halpern, MD, Marco Mielcarek, MD, Elihu H. Estey, MD, Brent L. Wood, MD PhD, Frederick R. Appelbaum, MD, Roland B. Walter, MD PhD MS

Blood (2015) 126 (23): 173.

https://doi.org/10.1182/blood.V126.23.173.173

Published: 2015

Journal Articles

A Prospective Multicenter Study of Nonmyeloablative Conditioning with TBI or Fludarabine/TBI for HLA-Matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies with Post Grafting Immunosuppression with Tacrolimus and Mycophenolate Mofetil: 10-Year Experience

Huiying Qiu, MD, Brenda M. Sandmaier, MD, Barry E. Storer, PhD, Thomas Chauncey, MD PhD, Finn Petersen, MD, Michael A. Pulsipher, Benedetto Bruno, MD, Mary Flowers, MD, Marco Mielcarek, MD, Rainer Storb, MD, David G Maloney, MD PhD

Blood (2015) 126 (23): 1949.

https://doi.org/10.1182/blood.V126.23.1949.1949

Published: 2015

Journal Articles

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Is It Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?

Daisuke Araki, MD, Brent L Wood, MD PhD, Megan Othus, PhD, Jerald P. Radich, MD, Anna B. Halpern, MD, Yi Zhou, MD PhD, Marco Mielcarek, MD, Elihu H. Estey, MD, Frederick R. Appelbaum, MD, Roland B. Walter, MD PhD MS

Blood (2015) 126 (23): 2571.

https://doi.org/10.1182/blood.V126.23.2571.2571

Published: 2015

Journal Articles

Posttransplant Cyclophosphamide for Prevention of Graft-Versus-Host Disease after HLA-Matched Related and Unrelated Donor Peripheral Blood Stem Cell Transplantation

Marco Mielcarek, MD, Terrence Furlong, Paul V. O'Donnell, MD PhD, Barry E. Storer, PhD, Rainer F. Storb, MD, Paul A. Carpenter, MD, Paul J. Martin, MD

Blood (2014) 124 (21): 1161.

https://doi.org/10.1182/blood.V124.21.1161.1161

Published: 2014

Journal Articles

Post-Transplantation Cyclophosphamide Following Busulfan and Fludarabine Myeloablative Conditioning Prevents Severe Acute and Chronic Graft-Versus-Host Disease and Minimizes Duration Of Immunosuppression: Results Of a Multi-Institutional Trial In Patients With High-Risk Hematologic Malignancies

Christopher G. Kanakry, MD, Paul O’Donnell, MD, PhD, Terry Furlong, NP, Marcos J de Lima, MD, Wei Wei, MS, Marta Medeot, MD, Marco Mielcarek, MD, Richard E Champlin, MD, Richard J. Jones, Peter F. Thall, PhD, Borje S. Andersson, MD, PhD, Leo Luznik

Blood (2013) 122 (21): 3310.

https://doi.org/10.1182/blood.V122.21.3310.3310

Published: 2013

Journal Articles

The Effect Of Donor and Recipient Statin Treatment On Infections After Allogeneic Hematopoietic Cell Transplantation

Sachiko Seo, MD, Michael Boeckh, MD, Barry E. Storer, PhD, Mark M Schubert, DDS, MSD, Marcello Rotta, MD, Brenda M. Sandmaier, MD, Marco Mielcarek, MD

Blood (2013) 122 (21): 4548.

https://doi.org/10.1182/blood.V122.21.4548.4548

Published: 2013

Journal Articles

Efficacy and Safety Of Lower-Dose Glucocorticoids For Initial Treatment Of Acute Graft-Versus-Host Disease: A Randomized Controlled Trial

Marco Mielcarek, MD, Terrence Furlong, Barry E. Storer, PhD, Margaret L. Green, MD, Paul A. Carpenter, MD, George B McDonald, MD, Mary E. D. Flowers, MD, Rainer Storb, MD, Frederick R. Appelbaum, MD, Michael Boeckh, MD, Paul J. Martin, MD

Blood (2013) 122 (21): 703.

https://doi.org/10.1182/blood.V122.21.703.703

Published: 2013

Journal Articles

Transplantation of Peripheral Blood Cells As Compared with Bone Marrow From HLA-Identical Related Donors Is Associated with Superior Long-Term Outcomes

Marco Mielcarek, MD, Barry Storer, PhD, Paul J. Martin, MD, Robert S Negrin, MD, Stephen J. Forman, MD, Mary E.D. Flowers, MD, Yoshihiro Inamoto, MD, Thomas Chauncey, MD, PhD, Rainer Storb, MD, Frederick R. Appelbaum, MD, William I Bensinger, MD

Blood (2011) 118 (21): 319.

https://doi.org/10.1182/blood.V118.21.319.319

Published: 2011

Journal Articles

Treatment of Recurrent or Persistent AML/MDS After Allogeneic Hematopoietic Cell Transplantation with Azacitidine.

Jennifer Vaughn, MD, MSPH, Barry Storer, PhD, Marco Mielcarek, MD, Edus H. Warren, III, MD, PhD, Paul J. Martin, MD, Brenda M. Sandmaier, MD, Elihu H. Estey, MD, Rainer Storb, MD, H. Joachim Deeg, MD, Bart Lee Scott, MD

Blood (2010) 116 (21): 1288.

https://doi.org/10.1182/blood.V116.21.1288.1288

Published: 2010

Journal Articles

Risk Factors for the Development of Acute and National Institute of Health (NIH) Chronic Graft-Versus-Host Disease (GVHD).

Mary E.D. Flowers, MD, Barry E. Storer, PhD, Stephanie J. Lee, MD, MPH, Paulo Vidal Campregher, MD, Afonso Celso Vigorito, MD, PhD, Paul A. Carpenter, MD, Marco Mielcarek, MD, Frederick R. Appelbaum, MD, Paul J. Martin, MD

Blood (2009) 114 (22): 345.

https://doi.org/10.1182/blood.V114.22.345.345

Published: 2009

Journal Articles

Falling Serum Albumin Predicts Severity of Acute Graft-Vs.-Host Disease and Non-Relapse Mortality After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation.

Andrew R. Rezvani, MD, Barry E. Storer, PhD, Rainer F. Storb, MD, Marco Mielcarek, MD, David G. Maloney, MD, PhD, Brenda M. Sandmaier, MD, Paul J. Martin, MD, Mary E. D. Flowers, MD, George B. McDonald, MD

Blood (2009) 114 (22): 1146.

https://doi.org/10.1182/blood.V114.22.1146.1146

Published: 2009

Journal Articles

In Vivo Modulation of T Cell and Monocyte Function Following Infusion of Mesenchymal Stromal Cells (MSC)

Cristina Castilla-LLorente, MD., PHD., Mineo Iwata, Marco Mielcarek, MD, PhD, V. Kraig Abrams, BS., Billanna Hwang, BS, Richard A. Nash, MD, Beverly Torok-Storb, PhD

Blood (2008) 112 (11): 4739.

https://doi.org/10.1182/blood.V112.11.4739.4739

Published: 2008

Journal Articles

A Novel SNP-Based Method for Assessing Langerhans Cell Chimerism Following Hematopoietic Stem Cell Transplantation in Humans.

A. Yasmine Kirkorian, Matthew P Collin, MD, PhD, Marco Mielcarek, MD, Wandi Zhang, Donna Neuberg, ScD, Catherine J Wu, MD, Miriam Merad, MD, PhD

Blood (2008) 112 (11): 2328.

https://doi.org/10.1182/blood.V112.11.2328.2328

Published: 2008

Journal Articles

Intensive Supportive Care and Cytokines Promote Recovery of Hematopoiesis after Total Body Irradiation (TBI) without Hematopoietic Stem Cell Support.

George E. Georges, MD, Jyothi Pillai, MD, Vladimir Lesnikov, PhD, Marco Mielcarek, MD, Marina Lesnikova, PhD, Ya-Ju Laura Yang, BS, Anna Aragon, BS

Blood (2007) 110 (11): 1193.

https://doi.org/10.1182/blood.V110.11.1193.1193

Published: 2007

Journal Articles

Relapse Risk after Nonmyeloablative Hematopoietic Cell Transplantation for Malignant Diseases.

Christoph Kahl, MD, Barry Storer, PhD, Marco Mielcarek, MD, Mike Maris, MD, Brenda Sandmaier, MD, David Maloney, MD, PhD, Thomas Chauncey, MD, Dietger Niederwieser, MD, Peter McSweeney, MD, Benedetto Bruno, MD, Karl Blume, MD, James Wade, MD, Jose Leis, MD, PhD, Emilia Langston, MD, Michael Pulsipher, MD, Edward Agura, MD, Rainer Storb, MD

Blood (2005) 106 (11): 703.

https://doi.org/10.1182/blood.V106.11.703.703

Published: 2005

Journal Articles

Nonmyeloablative and Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies: Outcomes with HLA-Matched Unrelated Donors Compared to HLA-Identical Sibling Donors.

Marco Mielcarek, MD, Barry Storer, PhD, Christoph Kahl, MD, Brenda M. Sandmaier, MD, David Maloney, MD, PhD, Mike B. Maris, MD, Rainer Storb, MD

Blood (2005) 106 (11): 658.

https://doi.org/10.1182/blood.V106.11.658.658

Published: 2005

Journal Articles

Prognostic Relevance of “Early-Onset” Graft-Versus-Host Disease Following Nonmyeloablative Hematopoietic Cell Transplantation.

Marco Mielcarek, MD, Lauri Burroughs, MD, Wendy Leisenring, PhD, Paul Martin, MD, Razvan Diaconezcu, MD, Brenda Sandmaier, MD, David Maloney, MD, PhD, Thomas Chauncey, MD, PhD, Michael Maris, MD, Judith Shizuru, MD, Karl Blume, MD, Ute Hegenbart, MD, Dietger Niederwieser, MD, Stephen Forman, MD, Benedetto Bruno, MD, Ann Woolfrey, MD, Rainer Storb, MD

Blood (2004) 104 (11): 423.

https://doi.org/10.1182/blood.V104.11.423.423

Published: 2004

NARROW

Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizumab, in Subjects with Newly Diagnosed Acute Graft Versus Host Disease

Pre-Transplant Monocytic Myeloid-Derived Suppressor Cell Frequency Has No Prognostic Role for Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Remission

Sirolimus Combined with Mycophenolate Mofetil (MMF) and Cyclosporine (CSP) Significantly Improves Prevention of Acute Graft-Versus-Host-Disease (GVHD) after Unrelated Hematopoietic Cell Transplantation (HCT): Results from a Phase III Randomized Multi-Center Trial

Significance of Peri-Transplant Dynamics of Minimal Residual Disease (MRD) in Adults with Acute Myeloid Leukemia (AML) in Morphological Remission Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation

A Prospective Multicenter Study of Nonmyeloablative Conditioning with TBI or Fludarabine/TBI for HLA-Matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies with Post Grafting Immunosuppression with Tacrolimus and Mycophenolate Mofetil: 10-Year Experience

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Is It Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?

Posttransplant Cyclophosphamide for Prevention of Graft-Versus-Host Disease after HLA-Matched Related and Unrelated Donor Peripheral Blood Stem Cell Transplantation

Post-Transplantation Cyclophosphamide Following Busulfan and Fludarabine Myeloablative Conditioning Prevents Severe Acute and Chronic Graft-Versus-Host Disease and Minimizes Duration Of Immunosuppression: Results Of a Multi-Institutional Trial In Patients With High-Risk Hematologic Malignancies

The Effect Of Donor and Recipient Statin Treatment On Infections After Allogeneic Hematopoietic Cell Transplantation

Efficacy and Safety Of Lower-Dose Glucocorticoids For Initial Treatment Of Acute Graft-Versus-Host Disease: A Randomized Controlled Trial

Transplantation of Peripheral Blood Cells As Compared with Bone Marrow From HLA-Identical Related Donors Is Associated with Superior Long-Term Outcomes

Treatment of Recurrent or Persistent AML/MDS After Allogeneic Hematopoietic Cell Transplantation with Azacitidine.

Risk Factors for the Development of Acute and National Institute of Health (NIH) Chronic Graft-Versus-Host Disease (GVHD).

Falling Serum Albumin Predicts Severity of Acute Graft-Vs.-Host Disease and Non-Relapse Mortality After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation.

In Vivo Modulation of T Cell and Monocyte Function Following Infusion of Mesenchymal Stromal Cells (MSC)

A Novel SNP-Based Method for Assessing Langerhans Cell Chimerism Following Hematopoietic Stem Cell Transplantation in Humans.

Intensive Supportive Care and Cytokines Promote Recovery of Hematopoiesis after Total Body Irradiation (TBI) without Hematopoietic Stem Cell Support.

Relapse Risk after Nonmyeloablative Hematopoietic Cell Transplantation for Malignant Diseases.

Nonmyeloablative and Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies: Outcomes with HLA-Matched Unrelated Donors Compared to HLA-Identical Sibling Donors.

Prognostic Relevance of “Early-Onset” Graft-Versus-Host Disease Following Nonmyeloablative Hematopoietic Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only